



Available online freely at www.isisn.org

Bioscience Research

Print ISSN: 1811-9506 Online ISSN: 2218-3973

Journal by Innovative Scientific Information and Services Network



RESEARCH ARTICLE

BIOSCIENCE RESEARCH, 2021 18(2): 1720-1732.

OPEN ACCESS

Bacterial infection in Diabetic foot

Jumanah Abdulhafiz Turkistani¹, Hind A. A. Al-Zahrani¹ and Nagwa Thabet Elsharawy^{1,2}

¹University of Jeddah, Collage of Science, Department of Biology, Jeddah, **Saudi Arabia**

²Department of Food Hygiene, Faculty of Veterinary Medicine, New Valley University, **Egypt**

*Correspondence: dr.nagwa2004@yahoo.com Received 15-10-2020, Revised: 03-06-2021, Accepted: 15-06-2021 e-Published: 29-06-2021

Diabetes mellitus (DM) is considered to be one of the most widespread chronic diseases, with almost 10% of the global adult population being diabetic or at risk of developing diabetes, characterized by high plasma glucose concentrations as a result of the inability of the body to adequately produce or use insulin effectively. Diabetes mellitus has been categorized into 3 main types; insulin-dependent diabetes mellitus, non-insulin-dependent, gestational diabetes mellitus. Several complications associated with Diabetes. The long-term vascular problems of diabetes are the most damaging impact, "microvascular disorders", "neuropathy," eye or "retinopathy," and "nephropathy". Diabetic Foot Infections (DFIs) are described as Extensive soft tissue necrosis (ulcers) which are correlated with chronic infections (DFIs). Methicillin-resistant *S. aureus* "MRSA" oversaw hospital outbreaks. Diabetes people are exposed to both CA and HA-MRSA due to frequent ulceration and sores. The increase in MRSA soft tissue infections was mainly driven by more community-acquired infections rather than health-care-associated strains. MRSA can cause a variety of infections, such as; pneumonia, osteoarticular infections, toxic shock syndrome, and bacteremia that might be progress to endocarditis or severe sepsis. DFIs treated surgically and or clinical therapy.

Keywords: Diabetes mellitus, Complications, nephropathy, Diabetic foot ulcer, MRSA, *Staphylococcus aureus*.

INTRODUCTION

Diabetes mellitus (DM) is considered to be one of the most widespread chronic diseases, with almost 10% of the global adult population being diabetic or at risk of developing diabetes, characterized by high plasma glucose concentrations as a result of the inability of the body to adequately produce or use insulin effectively. The disease is diagnosed when there is impaired glucose tolerance and characterized by high plasma glucose concentrations (International Diabetes Federation, 2015; World Health Organization, 2016; Jneid et al. 2018 and Atlas, 2019).

Diabetes mellitus has been categorized into 3 main types (International Diabetes Federation, 2015). Type 1 diabetes mellitus is an autoimmune

disease that much of the time starts with individuals affected before they reach 40 and is classified as juvenile-onset or insulin-dependent diabetes mellitus. It is marked by self-destructing insulin, which produces beta cells in the pancreas by the body's immune system response. About 10–15 percent of all cases of diabetes mellitus Type 1 diabetes mellitus, (T2DM) are stated to be a formerly named diabetes mellitus that was non-insulin-dependent that is often referred to as late-consumption diabetes. The peculiarity of this kind has its relative insulin deficiency and susceptibility to plasma glucose production. Which accounts for approximately 90 % of all diabetes cases worldwide. The third type is gestational diabetes mellitus (GDM), which is characterized by glucose intolerance which occurs

first or has been first diagnosed after an oral glucose test throughout pregnancy (Landon, 2010 and American Diabetes Association, 2012).

Multiple problems relate to diabetes. Mortality-associated severe metabolic risks include excessive higher blood glucose (hyperglycemia) diabetic ketoacidosis, and low blood glucose comas (hypoglycemia). the most devastating consequence of diabetes, its long-term vascular complications. These are wide-range risks and at least partially because of the chronic increase in blood glucose levels contributing to blood vessel damage (Forbes and Cooper, 2013).

Diabetic Foot Infections (DFIs) are described as Extensive soft tissue necrosis (ulcers) which are correlated with chronic infections (DFIs). These ulcer infections are often too frequently accompanied by amputation since the ecology of such infections has little or no knowledge to management of eradication of chronic infection (Dowd et al. 2008 and Lipsky et al. 2016).

DFIs can be mono- or poly-microbial and may be caused by a large variety of pathogens aerobic Gram-positive cocci like *Staphylococcus aureus*, Gram-negative bacilli (*Klebsiella pneumoniae*, *Escherichia coli*, *P aeruginosa*), and anaerobes. The pathways behind the diabetes-bacterial infection relationship are little known (Gan, 2013, Serra et al. 2015; Dunyach-remy et al. 2016; Gyamfi-brobby, 2016; Stacey et al. 2019 and Viswanathan et al. 2019).

Antimicrobial resistance is one of the big challenges worldwide in the management and mitigation of fast-growing pathogens and microbial outbreaks. Since the 1970s, MRSA has been the primary source of nosocomial infections around the globe. In particular the growing development of antibiotic resistance to methicillin and vancomycin (Joshi et al. 2013).

There are a wide variety of bacterial foot diabetic infection with different degree of foot infections and/or foot ulcers all of them could diagnosed, treated and prevented by several route of manipulations. Explain all the above in construed and fully detailed method is the main purpose of this review article which aim to: Identifying the definitions and types of diabetic mellitus, diabetic complications, diabetic foot infection and/ or ulcer. Different bacterial foot infection, MRSA (definition and types), treatment and prevention routes of diabetic foot infection.

1. Diabetes mellitus

Diabetes mellitus (DM) is considered to be one of the most widespread chronic disease, with

almost 10% of global adult population being diabetic or at risk of developing diabetes, characterized by high plasma glucose concentrations as a result of the inability of the body to adequately produce or use insulin effectively. The disease is diagnosed when there is impaired glucose tolerance and characterized by high plasma glucose concentrations (International Diabetes Federation, 2015; World Health Organization, 2016; Jneid et al. 2018 and Atlas, 2019).

In addition, guidelines are summarized for the specific diagnosis of biochemistry in fasting, oral glucose tolerance tests as well as the usage of hemoglobin A1c (HbA1c). The rising incidence of diabetes calls for targeted screening of risk populations for diabetes and prediabetes. This provides the foundation for the early implementation of interventions to prevent and prolong the development of diabetes in these risk categories. (Wochenschr et al. 2019)

2. Types of Diabetes mellitus

Diabetes mellitus has been categorized into 3 main types (International Diabetes Federation, 2015). Type 1 diabetes mellitus is an autoimmune disease that much of the time starts with individuals affected before they reach 40 and is classified as juvenil-onset or insulin-dependent diabetes mellitus. It is marked by self-destructing insulin, which produces beta cells in the pancreas by the body's immune system response. About 10–15 percent of all cases of diabetes mellitus Type 1 diabetes mellitus, (T2DM) are stated to be a formerly named diabetes mellitus that was non-insulation-dependent that is often referred to as late-consumption diabetes. The peculiarity of this kind is its relative insulin deficiency and susceptibility to plasma glucose production. Which accounts for approximately 90 % of all diabetes cases worldwide. The third type is gestational diabetes mellitus (GGD), which is defined by first or first diagnosed glucose sensitivity after an oral glucose test in pregnancies after an oral glucose tolerance test. Glucose resistance may be normal, but pregnant women with a family history of diabetes, elevated maternal age, obesity, and higher ethnicity can again be popular. These mothers' babies are expected to become obese and have a poor glucose tolerance (Landon, 2010; American Diabetes Association, 2012 and Gyamfi-brobby, 2016).

3. Complications of Diabetes

Several complications associated with Diabetes. Acute metabolic complications to mortality include unusually elevated blood glucose (hyperglycemia) diabetic ketoacidosis and low blood glucose coma (hypoglycemia). The long-term vascular problems of diabetes are the most damaging impact. These problems are common and are at least partially triggered by the continual rise in blood glucose levels that contribute to blood vessel injury. In diabetes, the resultant conditions are categorized under "microvascular disorders" (because of disruption to tiny blood vessels). Microvascular complications involve neural damage or "neuropathy," eye or "retinopathy," and kidney disease termed "nephropathy," (Forbes and Cooper, 2013).

Macrovascular complications and microvascular complications

The principal macrovascular complications include accelerated cerebrovascular disease and accelerated cardiovascular disease resulting in myocardial infarction stroke. While underlying etiology tends to be controversial, myocardial disease with diabetes now seems to be at least partially atherosclerosis independent. Other chronic diabetic problems is Depression dementia and sexual dysfunction (Williamson, 2005; Adeniyi et al. 2010; Thorve et al. 2011; Nouwen et al. 2011; Forbes and Cooper, 2013).

Neuropathy

More than half of all diabetes patients experience neuropathy, with a chance of one or more lower limb amputations for life projected to be up to 15 percent in certain communities. Neuropathy can also develop and can be a significant cause of compromised wound healing, erectile dysfunction, and cardiovascular diabetes disease. The occurrence of vascular defects such as capillary membrane thickening and endothelial hyperplasia with a resulting reduction of oxygen stress and hypoxia have historically clinically characterized the progression of the condition of neuropathy. Advanced diabetic neuropathy attributable to nerve fiber degradation is marked by altered vibrational and thermal sensitivities that contribute to sensory loss of perception. Hyperalgesia, paresthesia, and allodynia are also recorded in 40-50 % of patients with diabetic neuropathy with discomfort. Few diabetics often have discomfort without clinical proof of neuropathy (10-20 percent), which can significantly affect the quality of life (Obrosova,

2009; Abbott et al. 2011 and Forbes and Cooper, 2013).

Neurons are also significant in scale. In diabetes, longer nerve fibers tend to be exhibiting an earlier lack of nerve conduction velocities with a lack of nerve terminals. Therefore, tingling and lack of feeling and reflexes are always found first in the feet and then rising to impact other places, particularly the hands. It is generally referred to as a delivery of "gloves and stocking," which entails numbness, dysesthesia (pins and needles), loss sensory, and nightly discomfort. Spatial knowledge of the limb position is often early influenced during the disorder. It often includes a sensation loss in reaction to trauma resulting in callous and other common foot injuries, which puts diabetic neuropathy patients at a high risk of foot and leg ulcers that eventually contribute to amputation. Some diabetics often suffer several fractures and grow a Charcot joint that is degenerative in weight-bearing joints, marked by bone loss and subsequent deformation. Progressive motor weakness in diabetic neuropathy is also normal, which may contribute to the dorsal turning of hand and toes digits (Forbes and Cooper, 2013).

Diabetic foot infections

Extensive soft tissue necrosis (ulcers) that are correlated with chronic infections is known as diabetic foot infections (DFIs). These ulcer infections are often too commonly accompanied by amputation since the ecology or regulation of this form of recurrent infection is little or no known and no understanding (Dowd et al. 2008 and Lipsky et al. 2016).

According to (Lipsky, 2004), A prominent and usual lesion is the compromised diabetic foot mal perforin ulceration. Diabetic foot ulcers may also have physiological changes in the mechanisms of microcirculation, neuronal activity and growth factor activation. Therefore, foot ulcer varies from that of non-diabetic cases of diabetic situations. In reality the presence of an ulcer raises the wound's vulnerability to bacterial infection. An aggressive infection grows with the adjoining expansion of deeper tissue from bacterial invasion to limb threatening infection above 2 cm of the ulcers.(Frykberg and Moines, 2002; Lipsky, 2004; Akbay and Elif, 2007; Gyamfi-brobbe, 2016 and Datta et al. 2019).

Multi-drug resistant species (MDROs) often infect diabetic foot ulcers due to poor care and inappropriate antibiotic treatment, chronic wound processing, frequent hospital admission,


neuropathy, nephropathy and peripheral vascular diseases (Gadepalli et al. 2006 and Datta et al. 2019).

The disease severity progresses from ulceration and infection, to gangrene that results in hospitalization, which often precedes lower-extremity amputation. Purulent drainage or curetted materials from infected ulcers provide the best specimen for bacterial culture. For decades the only way to establish the cause pathogen(s) in the DFI was to culturing wound collections. As

microorganisms on any skin wound are still present. DFIs can be mono- or poly-microbial and may be caused by a wide range of pathogens aerobic Gram-positive cocci like *Staphylococcus aureus*, Gram-negative bacilli (*Escherichia coli*, *Klebsiella pneumoniae*, *P. aeruginosa*), and anaerobes. The pathways behind the diabetes-bacterial infection relationship are poorly understood (Gan, 2013; Serra et al. 2015; Dunyach-remy et al. 2016; Gyamfi-brobby, 2016; Stacey et al. 2019 and Viswanathan et al. 2019).

Picture 1: Infected diabetic foot wounds according to (Wagner's grade)

 Grade (0): mild pre- or post ulcerative foot lesion	 Grade (1): partial/ full thickness ulcer pre- or post ulcerative foot lesion
 Grade (2): Probing to tendon or capsule	 Grade (3): deep with osteitis
 Grade (4): mild pre- or post ulcerative foot lesion	 Grade (5): whole foot gangrene

Picture 2: Macroscopic and Microscopic Different between *Staphylococcus aureus* and MRSA

Micro-organisms comprise both skin ulcers. The clinical diagnosis of foot infection is based on purulent ulcers or classic inflammatory symptoms (e.g. erythema, discomfort, tenderness, warmth, or induration). The other main markers of DFI are foul odor, the occurrence of necrosis, and delay of wound healing, despite optimum treatment. However, signs can differ according to the disease's etiology. There is no similar trend of clinical signs in both patients. In some patients, local inflammatory changes may be less prominent or absent. Pressure and tenderness may be diminished or absent in neuropathic patients, whereas erythema in vascular patients can be absent. Many DFI patients have no systemic characteristics such as fever or chills. The lack of systemic indications or symptoms suggests a dangerous deep infection (Williams et al. 2004 and Viswanathan et al. 2019).

Variability of bacterial virulence factors and

host susceptibility levels often must be taken into consideration. Indeed, the numerous species extracted from contaminated wounds have no comparable pathogenic influence, and an estimation of the intrinsic virulence ability of isolated bacteria to establish their true pathogens seems an excellent way to better classify the infection and differentiate between infections and colonization. Around 30% of the human population is colonized with *S. aureus*. Imports involve a large variety of clinical diseases (e.g., bacteremia, endocarditis, skin and soft tissue, osteoarticular infections, respiratory infections and apparatus-related infections).

The several factors of virulence and toxins produced by *S. aureus* are well defined during infection. Any specific characteristics may therefore be found in DFI. The purpose of this analysis is to explain position. DFI aureus and its toxin role in the production of the infection (Wertheim et al. 2005; Gemechu et al. 2013; Tong

et al. 2015; Serra et al. 2015 and Dunyach-remy et al. 2016).

Variability of bacterial virulence factors and host susceptibility levels often must be taken into consideration. Indeed, the numerous species extracted from contaminated wounds have no comparable pathogenic influence, and an estimation of the intrinsic virulence ability of isolated bacteria to establish their true pathogens seems an excellent way to better classify the infection and differentiate between infections and colonization. Around 30% of the human population is colonized with *S. aureus*. Imports involve a large variety of clinical diseases (e.g., bacteremia, endocarditis, skin and soft tissue, osteoarticular infections, respiratory infections and apparatus-related infections).

Picture 2 (A, C) revealed the macroscopic growth of *Staphylococcus aureus* on Blood Sheep agar compared with macroscopic growth of MRSA on same media while Picture 2 (B, D) revealed the microscopic growth of *Staphylococcus aureus* by gram stain compared with macroscopic growth of MRSA on same media.

MRSA Categories

There are three main categories of methicillin-resistant *S. aureus*. In the decade after its initial description, MRSA oversaw hospital outbreaks (health-care-associated MRSA (HA-MRSA)) in many parts of the world. The MRSA epidemiology was dramatically altered when individuals with no prior association with health-care (referred to as community-associated MRSA (CA-MRSA)) were observed, especially in Australia in the 1980s, and, in the 1990s, in the United States and non-healthy people, including infants. It has also been associated with livestock exposure since the mid-2000s (livestock-associated MRSA (LA-MRSA)) (Grant, 1992; Sanza et al. 2005; Voss et al. 2005; Chambers et al. 2009; Joshi et al. 2013 and Lee et al. 2018).

Diabetes people are exposed to both CA and HA-MRSA due to frequent ulceration and sores. The additional penicillin-binding protein (PBP2a) provided by MRSA, which has low binding affinities for most penicillin and cephem antibiotics. The resistance to methicillin is induced by the existence of the *mec* chromosome cassette element (Gunawardena et al. 2012; Ilyasu et al. 2018; Davoodabadi et al. 2016 and Viswanathan et al. 2019).

The most common causative agent in DFIs is *Staphylococcus aureus* and of these 23.7 percent were reported in a study as methicillin-resistant

Staphylococcus aureus (MRSA). DFIs are soft tissue or bone infections below the malleoli. They typically start as a skin ulceration where it extends from the skin into deeper subcutaneous tissues and/or bones contiguously in ~25 percent of instances. The affected foot ulcer normally precedes a total of 60 percent of amputations that may be mild or severe (Lipsky, 2004; Vardakas et al. 2008; Saseedharan et al. 2017 and Viswanathan et al. 2019).

Reports from diabetic foot centers in the late 1990s showed that 15 percent of all isolates were MRSA. Studies in the early 2000s found that proportions of MRSA isolates were dramatically higher than in 1990, up to 30%. The increase in MRSA soft tissue infections was mainly driven by more community-acquired infections rather than health-care-associated strains (Bader, 2008; Boucher et al., 2009; Echols, 2011; Jr, 2011; Sutcliffe, 2011; Lipsky et al. 2012 and Viswanathan et al. 2019).

In recent years, the strains of *Staphylococcus aureus* have grown to be more immune to multiple antibiotic forms, including first-line antibiotics including penicillin or oxacillin. Although Vancomycin is the main therapeutic agent for MRSA infections over the last 50 years, its effectiveness in the face of increased minimum inhibitory concentrations (MICs) is becoming increasingly concerned (Care et al. 2005 and Viswanathan et al. 2019).

MRSA Antibiotics resistance

In some reports, some patient has five times the chance of mortality by hospitalization with different forms of MRSA infection relative to equivalent patients without MRSA infection. In addition, a growing literature has shown that a strong minimum inhibitory vancomycin (MIC) concentration of MRSA strains damages bacteremia recovery or localized osteo-articular infections. These problems have contributed to new anti-MRSA agents, including linezolid, daptomycin, tigecyclin, ceftaroline, oritavancin, telavancin and dalbavancin, being developed and more commonly used. Gram negative species developing β -lactamases (ESBLs) in the wide range or carbapenemases are more interested as these show tolerances to most antibiotics. In the last decade, the risk of DFI isolating MDROs has risen. Many facets of wound microbiology are responsible for developing DFIs. DFIs are polymicrobial in nature (more than 1 form of bacterium), including microbial load, the variety of microbial profiles of *Staphylococcus* and

Streptococcus being most frequently culprits (Lipsky and Stoutenburgh, 2005; Vaudaux et al. 2012; Djahmi et al. 2013; Jugun et al. 2013; Lauf et al. 2014; Zenelaj et al. 2014; Das et al. 2014 and Viswanathan et al. 2019).

Swab culture performance showed 100% susceptibility, negative infection predictability, and pathogens identification, whereas specificities were lower (20 % to 40%). So, the diagnostic use of swab appears mainly to be the exclusion of a micro-organism as a real pathogen and not the confirmation of its role and the presence of infection. The cultivation method thus plays a role in identifying microorganisms (Demetriou et al., 2013; Noor et al. 2015).

***S. aureus* Initiation of infection**

S. aureus is normally triggered by bacterial transfer from the main reservoir of the nose to open microlesions and wounds on the skin (probably by hand contact). *S. aureus* surface proteins fibronectin-binding protein A (FnBPB), clumping factor A (ClfA), ClfB, Collagen adhesine (Cna) for example) bind to extracellular matrix protectors and enable bacteria to connect and multiply on injured tissue. *S. aureus* adheres to biofilms (i.e. sticky agglomerations in an extracellular matrix of micro-organisms; Biofilms promote mechanical intrusion tolerance, host protection and treatment of antibiotics on artificial plastic or metal structures, allow it *S. aureus* is a common cause of catheter-related or joint-replacement-related infections or ventilator-associated pneumonia. *S. aureus* is used to manipulate the resulting influx of polymorphonuclear leukocytes (PMNs). *S. aureus* that forms local inflammation (Kluytmans et al. 1995; Eiff et al. 2001; Foster et al. 2014; Vanhommerig et al. 2014 and Hanzelmann et al. 2016).

Bacteria that are phagocytized, many produce pore-forming peptides (phenol soluble modulins (PSMs)) and protein toxins (α -toxin, known as α -haemolysin) and several bi-component leukocides such as Panton-Valentine leucocidin (PVL)), which are species-specific hosts and bind to host leukocyte membranes, leading to pore formation and causing lytic cell death, subsequently raising bacterial virulence. Massive inflammation increased by *S. aureus* superantigen toxins, which bind to the major histocompatibility complex (MHC) of antigen presenting cells and activate a large percentage of non-specific T cells, leading to systemic hyper inflammation known as 'cytokine storms.' (Peschel and Sahl, 2006; Hussain et al.

2010; Ho et al. 2012; Strijp, 2013; Spaulding et al. 2013; Stapels et al. 2014 and Lee et al. 2018).

***S. aureus* Abscess formation**

It's the *S. aureus* coagulase proteins which produce fibrin pseudo capsules surrounding bacteria and infiltrated, preventing further leukocyte influx. *S. aureus* can inhibit opsonization by, for example, the formation of a polysaccharide microcapsule and prevention of the complement cascade. However, the microcapsule is missing from important MRSA clones (Laarman et al. 2010; Cheng et al. 2011 and Boyle-vavra et al. 2015).

4.5.2. Systemic infection

Abscesses may be interrupted later, releasing pus and live bacteria to the surface of the skin, either to facilitate pathogen dissemination or to induce bacteremia to the bloodstream. *S. aureus* endovascular can bind to endothelial surfaces and platelets, and this adhesion can cause endocarditis, facilitate metastatic abscesses or trigger bacterial abscess in endothelial cells where, the bacteria are difficult to reach by antibiotics and host defense molecules. The agglutinating function of coagulases is meant to lead to systemic blood clotting, and the massive release of molecular trends connected to microorganisms along with superantigen toxin-induced cytokine storms contributes to fulminant systemic inflammation, Sepsis and multi-organ dysfunction when bacterial endovascular dissemination cannot be contained (Chavakis et al. 2005; Weidenmaier et al. 2005; Löffler et al. 2014; Thomer et al. 2016 and Lee et al. 2018).

4.5.3. Regulation and adaptation

Most of *S. aureus* virulence factors are differentially regulated by the Accessory Gene regulator (Agr) Quorum Sensing System and other regulatory networks. Which reported that there are many toxins have a high capability to cause invasive infections even in healthy people. Diagnosis, screening and prevention MRSA can cause a variety of infections, such as; pneumonia, osteoarticular infections, toxic shock syndrome, and bacteremia that might be progress to endocarditis or severe sepsis (Le and Otto, 2015 and Lee et al. 2018).

Microbiological diagnosis

Microbiological specimens from which MRSA can be isolated can be widely categorized into

clinical and screening samples. Clinical samples (e.g. purulent discharge specimens, sputum, deep tissue and blood) are taken from people with complaints or signs to investigate active infection, while screening samples (e.g. nasal, perineal, and throat swab) are acquired for diagnosis of asymptomatic colonizing. To diagnose MRSA directly from clinical or screening samples or to classify MRSA from presumptive staphylococcal colonies derived from clinical samples, an array of phenotypic and non-phenotypic approaches may be used. For clinical diagnostics, phenotypic methods are normally preferred (Lee et al. 2018).

Phenotypic methods.

Pure *S. aureus* Cultivations and collected by putting clinical samples on the corresponding culture media may be screened using a disk diffusion system for methicillin resistance with applying a cefoxitin disk on supplementing Mueller-Hinton agar or Mueller-Hinton agar with 6 µg/ml Oxacillin and 4% NaCl (Clinical and Laboratory Standards Institute (CLSI) recommendations). Firstly, Oxacillin was administrated to detect MRSA; however, now Cefoxitin has a better inducer than Oxacillin and results in a clear identifiable phenotype. The disk-diffusion method need strict adherence time (reading after 24 hours) at temperature (35 °C) to prevent false negative results (Ryffel et al. 1994).

The susceptibility test guidelines described above enable the slow rising MRSA subpopulation to exceed measurable levels in a hetero resistant population. MRSA may rarely be susceptible to cefoxitin and oxacillin and need an overnight exhibition of tolerance to low cefoxitin concentrations (Lee et al. 2018 and Penn et al. 2013).

Methicillin tolerance may also be observed by an antigen–antibody based latex agglutination test that detects penicillin-binding protein (PBP2a) by using an anti-PBP2a antibody in *S.aureus* colonies and cultures. Several automatic methods for detection and staphylococci antimicrobial resistance monitoring have also shown high sensitivities and unique characteristics for the MRSA strains studied (Winstanley and Courvalin, 2011 and Lee et al. 2018).

Prevention of MRSA Infection

MRSA management interventions through healthcare services have been extensively applied. These strategies seek to reduce the occurrence of MRSA by the diligent application of antimicrobial agents (including introducing

restrictions on their prescription), Monitor the carrier reservoir, prevent MRSA transmission among patients and prevent the development of infection in carriers. Several methods are typically required to avoid transmission and MRSA infection successfully. The management segment addresses decolonization, an significant control action for which increasing evidence is accessible (Calfee et al. 2015 and Lee et al. 2018).

Hand hygiene

Health workers can gain MRSA in their hands by contacting patients with MRSA colonization and handling equipment contaminated with MRSA and MRSA can therefore be transmitted between the patients. Hand hygiene aims at reducing MRSA spread through this route with alcohol-based hand rubbing or soap and water. Indeed, the WHO has recognized hand hygiene as an essential factor in healthy patient treatment and has given specific guidance on the proper practices of hand hygiene for health workers (Sax et al. 2007 and World Health Organization, 2009).

The quality of enhancing the conformity of MRSA healthcare staff with hand hygiene was demonstrated at both national and local levels. For example, a decline in the occurrence of MRSA bacteremia from 1.88 to 0.91 per 10.000 patient bedding days was related to a national hand hygiene initiative in England and Wales at the end of 2004. While the hand hygiene program was carried out alongside other national infection prevention programs, improved alcohol rub procurement during the program was separately related to a decline in the rate of MRSA bacteremia after changes for all other measures (Pittet et al. 2000; Cookson et al. 2012 and Lee et al. 2018).

Treatment method in diabetic foot

5.1. Surgically

1. Consult a surgical consultant in selected mild and severe cases of DFIs.
2. In most situations, immediate surgical intervention is required abscesses, separation syndrome and nearly all deep tissue necrotizing infections.
3. In cases of osteomyelitis followed by soft tissue inflammation, it is normally advisable to suggest surgical operation, soft tissue envelope damaged, X-ray bone destruction incremental, or ulcer bone. (Lipsky et al., 2016).

5.2. Antimicrobial therapy

1. Almost diabetic foot injuries are responsive to antimicrobial therapy, do not treat diabetic foot injuries clinically contaminated with antimicrobial therapy.
2. Choose antibiotic agents for care based on probable or confirmed causative pathogens, antibiotic resistance, clinical seriousness, DFI effectiveness and costs.
3. For most soft-tissue DFIs, antibiotic treatment lasts 1–2 weeks is generally acceptable.

Initially offer parenteral medication with most critical and some minor infections, then turn to oral care when the infection reacts (Lipsky et al. 2016)

CONCLUSION

DFIs may contaminated by different microorganisms that varies in their severity, MRSA is one of the most serious microorganisms' group that may contaminate DFIs. The increase in MRSA soft tissue infections was mainly driven by more community-acquired infections rather than health-care-associated strains. The most common protocol of treating DFIs is surgically and or clinical therapy.

CONFLICT OF INTEREST

The authors declared that present study was performed in absence of any conflict of interest.

ACKNOWLEDGEMENT

The article fully funded by the first author.

AUTHOR CONTRIBUTIONS

JAT: shared in photography, shared in study design, write, revised the manuscript. HAA: revised the manuscript. NTE: Corresponding author of the manuscript, study design, drafted and revised the manuscript, and data analysis. All authors read and approved the final manuscript.

Copyrights: © 2021@ author (s).

This is an open access article distributed under the terms of the [Creative Commons Attribution License \(CC BY 4.0\)](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply

with these terms.

REFERENCES

- Abbott, C. A., Malik, R. A., Ross, E. R. E. VAN, Kulkarni, J., and Boulton, A. J. M. (2011). *Prevalence and Characteristics of Painful Diabetic Neuropathy in a Large Community-Based Diabetic Population in the U.K.* 34(12). <https://doi.org/10.2337/dc11-1108>
- Akbay, E., and Elif, S. (2007). *Risk factors for infection of the diabetic foot with multi-antibiotic resistant microorganisms.* <https://doi.org/10.1016/j.jinf.2006.08.013>
- Bader, M. S. (2008). *Diabetic Foot Infection.*
- Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., and Bartlett, J. (2009). *Bad Bugs , No Drugs : No ESKAPE ! An Update from the Infectious Diseases Society of America.* 02111, 1–12. <https://doi.org/10.1086/595011>
- Boyle-vavra, S., Li, X., Alam, T., Read, T. D., Sieth, J., Cywes-bentley, C., Dobbins, G., David, M. Z., Kumar, N., Eells, S. J., Miller, L. G., Boxrud, D. J., Chambers, H. F., Lynfield, R., Lee, J. C., and Daum, S. (2015). *USA300 and USA500 Clonal Lineages of Staphylococcus aureus Do Not Produce a Capsular Polysaccharide Due to Conserved Mutations in the cap5 Locus.* 6(2), 1–10. <https://doi.org/10.1128/mBio.02585-14>.Editor
- Calfee, D. P., Salgado, C. D., Milstone, A. M., Harris, A. D., Kuhar, D. T., Moody, J., Aureden, K., Huang, S. S., Maragakis, L. L., Yokoe, D. S., Calfee, D. P., Salgado, C. D., Milstone, A. M., Harris, A. D., Kuhar, D. T., Moody, J., Aureden, K., Huang, S. S., Maragakis, L. L., ... Milstone, A. M. (2015). *Control: Strategies to Prevent Methicillin-Resistant Staphylococcus aureus Transmission and Infection in Acute Care Hospitals: 2014 Update How to cite this article: Strategies to Prevent Methicillin-Resistant Staphylococcus aureus Transmission and Infe.* 2014, 772–796. <https://doi.org/10.1086/676534>
- Care, A., Ladd, E., and Gnp, F. N. P. (2005). *The Use of Antibiotics for Viral Upper Respiratory Tract Infections: An Analysis of Nurse Practitioner and Physician Prescribing Practices in.* 17(10), 1997–2001.
- Chambers, H. F., Deleo, F. R., and Mountain, R. (2009). *Waves of resistance: Staphylococcus aureus in the antibiotic era.* 7(SEPTEMBER),

- 629–641.
<https://doi.org/10.1038/nrmicro2200>
- Chavakis, T., Wiechmann, K., Preissner, K. T., and Herrmann, M. (2005). *Staphylococcus aureus* interactions with the endothelium: the role of bacterial “secretable expanded repertoire adhesive molecules” (SERAM) in disturbing host defense systems. 94, 278–285.
- Cheng, A. G., Dedent, A. C., Schneewind, O., and Missiakas, D. (2011). A play in four acts: *Staphylococcus aureus* abscess formation. *Trends in Microbiology*, 19(5), 225–232.
<https://doi.org/10.1016/j.tim.2011.01.007>
- Cookson, B., Hayward, A., Cooper, B., Duckworth, G., Michie, S., and Murray, M. (2012). *Evaluation of the national Cleanyourhands campaign to reduce Staphylococcus aureus bacteraemia and Clostridium difficile infection in hospitals in England and Wales by improved hand hygiene: four year, prospective, ecological, interrupted time series*. 3005(May), 1–11.
<https://doi.org/10.1136/bmj.e3005>
- Das, A. F., Ph, D., and Dunne, M. W. (2014). *Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection*. 2169–2179.
<https://doi.org/10.1056/NEJMoa1310480>
- Datta, P., Chander, J., Gupta, V., Mohi, G. K., and Attri, A. K. (2019). *Evaluation of various risk factors associated with multidrug - resistant organisms isolated from diabetic foot ulcer patients*. 58–62.
<https://doi.org/10.4103/JLP.JLP>
- Davoodabadi, F., Mobasherizadeh, S., Mostafavizadeh, K., Shojaei, H., and Havaei, S. A. (2016). *Nasal colonization in children with community acquired methicillin-resistant Staphylococcus aureus*.
<https://doi.org/10.4103/2277-9175.182217>
- Demetriou, M., Papanas, N., Panopoulou, M., Papatheodorou, K., and Bounovas, A. (2013). *The International Journal of Lower Extremity Wounds Tissue and Swab Culture in Diabetic Foot Infections: Neuropathic Versus Neuroischemic Ulcers*.
<https://doi.org/10.1177/1534734613481975>
- Djahmi, N., Messad, N., Nedjai, S., Moussaoui, A., Mazouz, D., Richard, J. L., Sotto, A., and Lavigne, J. P. (2013). *Molecular epidemiology of Staphylococcus aureus strains isolated from inpatients with infected diabetic foot ulcers in an Algerian University Hospital*.
- Dunyach-remy, C., Essebe, C. N., Sotto, A., and Lavigne, J. (2016). *Staphylococcus aureus Toxins and Diabetic Foot Ulcers: Role in Pathogenesis and Interest in Diagnosis*. Table 1, 1–20.
<https://doi.org/10.3390/toxins8070209>
- Echols, R. M. (2011). *Understanding the regulatory hurdles for antibacterial drug development in the post-Ketek world*. 1241, 153–161.
<https://doi.org/10.1111/j.1749-6632.2011.06300.x>
- Eiff, C. Von, Becker, K., Machka, K., Stammer, H., and Peters, G. (2001). *nasal carriage as a source of staphylococcus aureus bacteremia*. 344(1), 11–16.
- Forbes, J. M., and Cooper, M. E. (2013). *Mechanisms of diabetic complications*. 137–188.
<https://doi.org/10.1152/physrev.00045.2011>
- Foster, T. J., Geoghegan, J. A., Ganesh, V. K., and Höök, M. (2014). *Adhesion, invasion and evasion: the many functions of the surface proteins of Staphylococcus aureus*. *Nature Publishing Group*, 12(1), 49–62.
<https://doi.org/10.1038/nrmicro3161>
- Frykberg, R. G., and Moines, D. (2002). *Diabetic Foot Ulcers: Pathogenesis and Management*. 1655–1662.
- Gadepalli, R., Dhawan, B., Sreenivas, V., Kapil, A., Ammini, A. C., and Chaudhry, R. (2006). *A Clinico-microbiological Study of Diabetic Foot Ulcers in an Indian Tertiary Care*. 29(8).
<https://doi.org/10.2337/dc06-0116>
- Gan, Y. (2013). *Host Susceptibility Factors to Bacterial Infections in Type 2 Diabetes*. 9(12), 1–3.
<https://doi.org/10.1371/journal.ppat.1003794>
- Gemechu, F. W., Seemant, F. N. U., and Curley, C. A. (2013). *Diabetic Foot Infections*.
- Ghotaslou, R., Memar, M., and A. N. (2019). *Classification, microbiology and treatment of diabetic foot infections*. *JOURNAL OF WOUND CARE*, 27.
- Grant, D. (1992). *Ten years' experience with methicillin-resistant Staphylococcus aureus in a large Australian hospital*.
- Gunawardena, N. D., Thevanesam, V., Kanakarathne, N., Abeysekera, D., and Ekanayake, A. (2012). *Molecular identification of methicillin resistance and virulence marker in staphylococcus aureus*. 393.
- Gyamfi-brobby, G. (2016). *WestminsterResearch*

- The microbiology of diabetic foot infections: a Ghanaian perspective.*
- Hanzelmann, D., Joo, H., Franz-wachtel, M., Hertlein, T., Stevanovic, S., Otto, M., Kretschmer, D., Peschel, A., Macek, B., Wolz, C., and Go, F. (2016). *lipopeptide shedding by bacterial surfactants.* <https://doi.org/10.1038/ncomms12304>
- Ho, C., Li, C., Ho, M., Lin, C., Liu, S., and Lu, J. (2012). *High Rate of qacA- and qacB-Positive Methicillin-Resistant Staphylococcus aureus Isolates from Chlorhexidine-Impregnated Catheter-Related Bloodstream Infections.* 56(11), 5693–5697. <https://doi.org/10.1128/AAC.00761-12>
- Htewehts, U. U., and Se, E. C. (1964). *resistant to methicillin , isoxazolyl penicillins , and cephalothin in staphylococcus aureus.*
- Hussain, M., Grundmeier, M., Bru, M., Lo, B., Varga, G., Roth, J., Kahl, B. C., Proctor, R. A., and Peters, G. (2010). *Staphylococcus aureus Panton-Valentine Leukocidin Is a Very Potent Cytotoxic Factor for Human Neutrophils.* 6(1). <https://doi.org/10.1371/journal.ppat.1000715>
- Iliyasu, G., Dayyab, F. M., Abubakar, S., Inuwa, S., Tambuwal, S. H., Tiamiyu, A. B., Habib, Z. G., Gadanya, M. A., Sheshe, A. A., Mijinyawa, M. S., Aminu, A., Adamu, M. S., Mande, K. M., and Habib, A. G. (2018). *Laboratory-confirmed hospital-acquired infections: An analysis of a hospital's surveillance data in Nigeria. Heliyon, July, e00720.* <https://doi.org/10.1016/j.heliyon.2018.e00720>
- InternationalDiabetesFederation. (2015). *IDF Diabetes Atlas* (Seventh Ed).
- Jneid, J., Cassir, N., Schuldiner, S., Jourdan, N., Sotto, A., Lavigne, J., and Scola, B. La. (2018). *Exploring the Microbiota of Diabetic Foot Infections With Culturomics.* 8(August), 1–8. <https://doi.org/10.3389/fcimb.2018.00282>
- Joshi, S., Hospital, P. D. H. N., Manchanda, V., Nehru, C., Chikitsalaya, B., Gautam, V., and Gupta, V. (2013). *Methicillin resistant Staphylococcus aureus (MRSA) in India: Prevalence and susceptibility pattern. October 2016.*
- Jr, R. C. M. (2011). *International Journal of Antimicrobial Agents Discovering new antimicrobial agents. International Journal of Antimicrobial Agents,* 37(1), 2–9. <https://doi.org/10.1016/j.ijantimicag.2010.08.018>
- Jugun, K., Vaudaux, P., and Garbino, J. (2013). *The safety and efficacy of high-dose daptomycin combined with rifampicin for the treatment of Gram-positive osteoarticular infections.* 1375–1380. <https://doi.org/10.1007/s00264-013-1856-y>
- Kluytmans, W., Mouton, W., Ijzerman, E. P. F., Maat, A. W. P. M., Wagenvoort, H. T., and Verbrugh, H. A. (1995). *Nasal Carriage of Staphylococcus aureus as a Major Risk Factor for Wound Infections after Cardiac Surgery.* 171(August 1994), 216–219.
- Laarman, A., Milder, F., and Strijp, J. Van. (2010). *Complement inhibition by gram-positive pathogens: molecular mechanisms and therapeutic implications.* 115–120. <https://doi.org/10.1007/s00109-009-0572-y>
- Landon, M. B. (2010). *Is there a benefit to the treatment of mild. YMOB,* 202(6), 649–653. <https://doi.org/10.1016/j.ajog.2010.02.006>
- Lauf, L., Mitha, I., Regöly-mérei, J., Embil, J. M., Cooper, A., Beth, M., Castaing, N., Dartois, N., Yan, J., Dukart, G., and Maroko, R. (2014). *Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis ☆ , ☆☆.* 78, 469–480. <https://doi.org/10.1016/j.diagmicrobio.2013.12.007>
- Le, K. Y., and Otto, M. (2015). *Quorum-sensing regulation in staphylococci — an overview.* 6(October), 1–8. <https://doi.org/10.3389/fmicb.2015.01174>
- Lee, A. S., Lencastre, H. De, Garau, J., Kluytmans, J., Malhotra-kumar, S., Peschel, A., and Harbarth, S. (2018). *Methicillin-resistant Staphylococcus aureus. Nature Publishing Group,* 4(May), 1–23. <https://doi.org/10.1038/nrdp.2018.33>
- Lipsky, B. A. (2004). *Medical Treatment of Diabetic Foot Infections.* 1597(Suppl 2).
- Lipsky, B. A., and Stoutenburgh, U. (2005). *Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections.* 55(2), 240–245. <https://doi.org/10.1093/jac/dkh531>
- Lipsky, B. A., Aragón-sánchez, J., Diggle, M., and Embil, J. (2016). *IWGDF guidance on the diagnosis and management of foot infections in persons with diabetes.* 32, 45–74. <https://doi.org/10.1002/dmrr>

- Lipsky, B. A., Berendt, A. R., Cornia, P. B., Pile, J. C., Peters, E. J. G., Armstrong, D. G., Deery, H. G., Embil, J. M., Joseph, W. S., Karchmer, A. W., Pinzur, M. S., and Senneville, E. (2012). *2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections* a. 54, 132–173. <https://doi.org/10.1093/cid/cis346>
- Löffler, B., Tuscherr, L., Niemann, S., and Peters, G. (2014). International Journal of Medical Microbiology *Staphylococcus aureus* persistence in non-professional phagocytes. *International Journal of Medical Microbiology*, 304(2), 170–176. <https://doi.org/10.1016/j.ijmm.2013.11.011>
- Lowy, F. D. (1998). *Staphylococcus aureus* Infections. *The New England Journal of Medicine*.
- Noor, S., Zubair, M., and Ahmad, J. (2015). Diabetes and Metabolic Syndrome: Clinical Research and Reviews Diabetic foot ulcer — A review on pathophysiology, classification and microbial etiology. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, 9(3), 192–199. <https://doi.org/10.1016/j.dsx.2015.04.007>
- Nouwen, A., Nefs, G., Caramlau, I., Connock, M., Lloyd, C. E., Peyrot, M., and Pouwer, F. (2011). *Prevalence of Depression in Individuals With Impaired Glucose Metabolism or Undiagnosed Diabetes*. 34. <https://doi.org/10.2337/dc10-1414>
- Obrosova, I. G. (2009). *Diabetic Painful and Insensate Neuropathy: Pathogenesis and Potential Treatments Prevalence, Current Treatment Options, And Limitations Of Existing*. 6(October), 638–647.
- Oyibo, S., Jude, E., Tarawneh, I., Nguyen, H., Harkless, L., and Boulton, A. J. M. (2001). *A Comparison of Two Diabetic Foot Ulcer Classification Systems*. 24(1).
- Penn, C., Moddrell, C., Tickler, I. A., Ann, M., Kehrl, M., Goering, R. V., and Tenover, F. C. (2013). Journal of Global Antimicrobial Resistance Wound infections caused by inducible methicillin-resistant *Staphylococcus aureus* strains. *Integrative Medicine Research*, 1(2), 79–83. <https://doi.org/10.1016/j.jgar.2013.03.009>
- Peschel, A., and Sahl, H. (2006). *The co-evolution of host cationic antimicrobial peptides and microbial resistance*. 4(July), 529–536. <https://doi.org/10.1038/nrmicro1441>
- Pittet, D., Hugonnet, S., Harbarth, S., Mourouga, P., Sauvan, V., and Touveneau, S. (2000). *Effectiveness of a hospital-wide programme to improve compliance with hand hygiene*. 356, 1307–1312.
- Ryffel, C., Strassle, A., Kayser, F. H., and Bergerbachi, B. (1994). *Mechanisms of Heteroresistance in Methicillin-Resistant Staphylococcus aureus*. 38(4), 724–728.
- Sanza, L. T., Como-sabetti, K., Jernigan, J. A., Harriman, K., Ph, D., Harrison, L. H., Lynfield, R., Farley, M. M., and Bacterial, A. (2005). *Methicillin-Resistant Staphylococcus aureus Disease in Three Communities*. 1436–1444.
- Saseedharan, S., Sahu, M., Chaddha, R., Pathrose, E., Bal, A., Bhalekar, P., Sekar, P., and Krishnan, P. (2017). Epidemiology of diabetic foot infections in a reference tertiary hospital in India. *Brazilian Journal of Microbiology*, 1–6. <https://doi.org/10.1016/j.bjm.2017.09.003>
- Sax, H., Allegranzi, B., Uc, I., and Pittet, D. (2007). ‘My five moments for hand hygiene’: a user-centred design approach to understand, train, monitor and report hand hygiene. <https://doi.org/10.1016/j.jhin.2007.06.004>
- Serra, R., Grande, R., Butrico, L., Rossi, A., Caroleo, B., Amato, B., Gallelli, L., and Franciscis, S. De. (2015). *Chronic wound infections: the role of Pseudomonas aeruginosa and Staphylococcus aureus*. 605–613.
- Spaulding, A. R., Salgado-pabón, W., Kohler, P. L., Horswill, A. R., Leung, D. Y. M., and Schlievert, M. (2013). *Staphylococcal and Streptococcal Superantigen Exotoxins*. 26(3), 422–447. <https://doi.org/10.1128/CMR.00104-12>
- Stacey, H. J., Clements, C. S., Welburn, S. C., and Jones, J. D. (2019). The prevalence of methicillin-resistant *Staphylococcus aureus* among diabetic patients: a meta-analysis. *Acta Diabetologica*, 0(0), 0. <https://doi.org/10.1007/s00592-019-01301-0>
- Stapels, D. A. C., Ramyar, K. X., Bischoff, M., Köckritz-blickwede, M. Von, and Milder, F. J. (2014). *Staphylococcus aureus* secretes a unique class of neutrophil serine protease inhibitors. 111(36), 13187–13192. <https://doi.org/10.1073/pnas.1407616111>
- Strijp, J. A. G. Van. (2013). *Neutrophils Versus Staphylococcus aureus: A Biological Tug of War* *. <https://doi.org/10.1146/annurev-micro-092412-155746>

- Sutcliffe, J. A. (2011). *Antibiotics in development targeting protein synthesis*. 1241, 122–152. <https://doi.org/10.1111/j.1749-6632.2011.06323.x>
- Thomer, L., Schneewind, O., and Missiakas, D. (2016). *Pathogenesis of Staphylococcus aureus Bloodstream Infections*. February, 343–364. <https://doi.org/10.1146/annurev-pathol-012615-044351>
- Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., and Fowler, V. G. (2015). *Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management*. 28(3), 603–661. <https://doi.org/10.1128/CMR.00134-14>
- Toole, R. D. O., Drew, W. L., Dahlgren, B. J., and Beaty, H. N. (1970). *An Outbreak of Staphylococcus aureus Infection*.
- Vanhommerig, E., Moons, P., Pirici, D., Lammens, C., Hernalsteens, J., Greve, H. De, Kumar-singh, S., and Goossens, H. (2014). *Comparison of Biofilm Formation between Major Clonal Lineages of Methicillin Resistant Staphylococcus aureus*. 9(8). <https://doi.org/10.1371/journal.pone.0104561>
- Vardakas, K. Z., Horianopoulou, M., and Falagas, M. E. (2008). *Factors associated with treatment failure in patients with diabetic foot infections: An analysis of data from randomized controlled trials*. 80, 344–351. <https://doi.org/10.1016/j.diabres.2008.01.009>
- Vaudaux, P., Ferry, T., Uçkay, I., and François, P. (2012). *Prevalence of isolates with reduced glycopeptide susceptibility in orthopedic device-related infections due to methicillin-resistant Staphylococcus aureus*. 3367–3374. <https://doi.org/10.1007/s10096-012-1705-8>
- Viswanathan, V., Pendsey, S., and Radhakrishnan, C. (2019). *aureus in Diabetic Foot Infection in India: A Growing Menace*. <https://doi.org/10.1177/1534734619853668>
- Voss, A., Loeffen, F., and Bakker, J. (2005). *Staphylococcus aureus in Pig Farming*. 11(12), 2004–2005.
- Weidenmaier, C., Peschel, A., Xiong, Y., Kristian, S. A., Dietz, K., Yeaman, M. R., and Bayer, A. S. (2005). *Lack of Wall Teichoic Acids in Staphylococcus aureus Leads to Reduced Interactions with Endothelial Cells and to Attenuated Virulence in a Rabbit Model of Endocarditis*. 191, 1771–1778.
- Wertheim, H. F. L., Melles, D. C., Vos, M. C., Leeuwen, W. Van, Belkum, A. Van, Verbrugh, H. A., and Nouwen, J. L. (2005). *The role of nasal carriage in Staphylococcus aureus infections*. 5(December), 751–762.
- Williams, D. T., Hilton, J. R., and Harding, K. G. (2004). *Diagnosing Foot Infection in Diabetes*. 83–86.
- Williamson, T. C. H. C. G. J. D. (2005). *Cognitive decline and dementia in diabetes — systematic overview of prospective observational studies*. 2460–2469. <https://doi.org/10.1007/s00125-005-0023-4>
- Winstanley, T., and Courvalin, P. (2011). *Expert Systems in Clinical Microbiology*. 24(3), 515–556. <https://doi.org/10.1128/CMR.00061-10>
- Wochenschr, W. K., Harreiter, J., and Roden, M. (2019). *Diabetes mellitus – Definition, Klassifikation, Diagnose, Screening und Prävention (Update 2019). Update*. <https://doi.org/10.1007/s00508-019-1450-4>
- World Health Organization. (2009). *WHO Guidelines on Hand Hygiene in Health Care. World Alliance for Patient Safety*.
- World Health Organization. (n.d.). *World Health Organization*. (2016). *World health statistics 2016: monitoring health for the SDGs sustainable development goals*. 2016 .. [https://books.google.com.sa/books?id=A4LDgAAQBAJandlpg=PP1andots=dcheYTdnwAanddq=\(World+Health+Organization%2C+2016\)andlrandhl=arandpg=PP1#v=onepageandqandf=false](https://books.google.com.sa/books?id=A4LDgAAQBAJandlpg=PP1andots=dcheYTdnwAanddq=(World+Health+Organization%2C+2016)andlrandhl=arandpg=PP1#v=onepageandqandf=false)
- Zenelaj, B., Bouvet, C., and Lipsky, B. A. (2014). *The International Journal of Lower Extremity Wounds*. <https://doi.org/10.1177/1534734614550311>